Drugs / Mik-beta-1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00019032 | Mar 1996 → ? | leukemia | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Mik-beta-1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00019032 ↗ |
| Known as | MOAB Mik-beta-1 | “Patients receive monoclonal antibody Mik-beta-1 (MOAB Mik-beta-1) IV over 2 hours on days 1, 4, 7, and 10.” NCT00019032 ↗ |
| Action | Inhibit | “Interleukin-2 receptor beta chain inhibitor” CHEMBL2109326 ↗ |
| Modality | Monoclonal antibody | “Patients receive monoclonal antibody Mik-beta-1” NCT00019032 ↗ |
| Route | Intravenous | “IV over 2 hours” NCT00019032 ↗ |
| Target | IL2RB | “Interleukin-2 receptor beta chain inhibitor” CHEMBL2109326 ↗ |